Target-specific immunoPET Imaging of Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 do 75 lat i płeć żeńska
- •Potwierdzony nowotwór piersi lub podejrzenie nowotworu na podstawie badań obrazowych
- •Zdolność do wyrażenia świadomej zgody i zgodność z wymogami badania
✗ Disqualifies
- •Ciąża
- •Poważne problemy z wątrobą lub nerkami
- •Duża operacja w ciągu ostatniego miesiąca
- •Alergia na przeciwciała lub radioaktywne leki przeciwciałowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- January 27, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China
Trial contact
Weijun Wei, Ph.D. & M.D.
Wenzhi Jia, Ph.D. & M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.